Searchable abstracts of presentations at key conferences in endocrinology

ea0081p169 | Pituitary and Neuroendocrinology | ECE2022

Identification of a novel SSTR3 full agonist and its activity in non-functioning pituitary adenoma model

Modena Daniela , Luisa Moras Maria , Sandrone Giovanni , Stevenazzi Andrea , Vergani Barbara , Dasgupta Pooja , Kliewer Andrea , Gulde Sebastian , Schillmaier Mathias , Luque Raul M. , Schulz Stefan , Pellegata Natalia , Steinkuhler Christian

Non-functioning pituitary adenomas (NFPAs), mainly gonadotroph pituitary adenomas (GPAs), are the second most common type of PAs. Given the lack of symptoms secondary to hormone hypersecretion, NFPAs are often diagnosed when they cause mass effects. At this stage they are invasive (50% of cases), they cannot be completely resected and often recur. Despite their frequency, no standard of care drug treatment currently exists for these tumors. SSAs (somatostatin agonists) like oc...

ea0099rc9.4 | Rapid Communications 9: Pituitary and Neuroendocrinology | Part II | ECE2024

The novel SST3 agonist ITF2984 exerts antimitotic and proapoptotic effects in human non-functioning pituitary neuroendocrine tumor (NF-PitNET) cells

Di Muro Genesio , Catalano Rosa , Treppiedi Donatella , Maria Barbieri Anna , Mangili Federica , Marra Giusy , Di Bari Sonia , Esposito Emanuela , Nozza Emma , Lania Andrea , Locatelli Marco , Modena Daniela , Steinkuhler Christian , Peverelli Erika , Mantovani Giovanna

Non-functioning pituitary neuroendocrine tumors (NF-PitNETs) are still orphan of medical therapy. The drmgs approved for the other types of PitNETs, e.g. somatostatin analogues (SSA) with high affinity for somatostatin receptors (SSTs) type 2 (SST2) and 5 (SST5) are poorly efficacious in NF-PitNETs. Among SSTs, NF-PitNETs express high levels of SST3, a receptor that can mediate antiproliferative and apoptotic signaling. ITF2984 is a pan-SST ligand with high affinity for SST3, ...